Business Description
ISIN : US22407B1089
Total Employee Number:
8Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.92 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 13.3 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 29.1 | |||||
3-Year EPS without NRI Growth Rate | 30.4 | |||||
3-Year FCF Growth Rate | 38.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -47.68 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.63 | |||||
9-Day RSI | 36.5 | |||||
14-Day RSI | 41.03 | |||||
3-1 Month Momentum % | 3.45 | |||||
6-1 Month Momentum % | -2.64 | |||||
12-1 Month Momentum % | -22.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.4 | |||||
Quick Ratio | 13.4 | |||||
Cash Ratio | 12.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.3 | |||||
Shareholder Yield % | -10.33 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -288.7 | |||||
Net Margin % | -270.23 | |||||
EBITDA Margin % | -288.45 | |||||
FCF Margin % | -196.07 | |||||
OCF Margin % | -196.07 | |||||
ROE % | -56.77 | |||||
ROA % | -50.16 | |||||
ROIC % | -1858.92 | |||||
3-Year ROIIC % | 637150 | |||||
ROC (Joel Greenblatt) % | -17512.1 | |||||
ROCE % | -59.38 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 9.32 | |||||
PB Ratio | 2.37 | |||||
Price-to-Tangible-Book | 2.37 | |||||
EV-to-EBIT | -2.57 | |||||
EV-to-Forward-EBIT | -1.14 | |||||
EV-to-EBITDA | -2.58 | |||||
EV-to-Revenue | 7.43 | |||||
EV-to-Forward-Revenue | 130.28 | |||||
EV-to-FCF | -3.79 | |||||
Price-to-GF-Value | 0.67 | |||||
| Price-to-Net-Current-Asset-Value | 2.4 | |||||
| Price-to-Net-Cash | 2.63 | |||||
Earnings Yield (Greenblatt) % | -38.91 | |||||
FCF Yield % | -15.3 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:COYA
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Coya Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8.019 | ||
| EPS (TTM) ($) | -1.07 | ||
| Beta | 0.7672 | ||
| 3-Year Sharpe Ratio | 0.35 | ||
| 3-Year Sortino Ratio | 0.58 | ||
| Volatility % | 55.54 | ||
| 14-Day RSI | 41.03 | ||
| 14-Day ATR ($) | 0.246853 | ||
| 20-Day SMA ($) | 4.7165 | ||
| 12-1 Month Momentum % | -22.71 | ||
| 52-Week Range ($) | 3.7101 - 7.75 | ||
| Shares Outstanding (Mil) | 23.46 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Coya Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Coya Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 61 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | 4.64 (-3.33%) | ||
| General meeting for 2026 | 2026-06-25 12:00 | 5.32 (-1.30%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 4.18 (+1.46%) | ||
| Annual report for 2026 | 2026-03-16 | 4.53 (-5.23%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-16 | 4.53 (-5.23%) | ||
| 18th Clinical Trials on Alzheimer\'s Disease (CTAD) Conference | 2025-12-02 15:10 | 6.24 (-4.15%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 6.01 (+0.67%) | ||
| Guidance call for 2025 | 2025-09-10 10:00 | 6.27 (-2.34%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 6.15 (+2.50%) |
Coya Therapeutics Inc Frequently Asked Questions
Guru Commentaries on NAS:COYA
We want to update you on our small investment in Coya Therapeutics (COYA). COYA is a clinical-stage biotechnology company whose lead drug, aimed at treating ALS (Lou Gehrig’s disease), has just entered clinical trials. While results won’t be known for about a year, the compound appears very promising and, if the trial succeeds, it has an excellent chance to receive 'fast track' approval from the FDA. COYA is a small position for us because its market capitalization is only about $100 million, and we are the largest shareholder. COYA’s scientific approach was recently profiled in Nature. Additionally, last week Dr. Shimon Sakaguchi – a member of COYA’s scientific advisory committee – was awarded the Nobel Prize in Medicine for his work on immunology in an area consistent with COYA’s approach. The Nobel Prize validates this science and underscores COYA’s leadership in advancing a potentially transformative new class of treatments.
Press Release
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
